Two years ago, the Food and Drug Administration approved a new drug for arthritis in dogs called Librela (bedinvetmab). Given by injection, the medicine reduces arthritis pain by binding to a protein called canine nerve growth factor (NGF). That prevents pain signals from reaching the brain.
To continue reading this article or issue you must be a paid subscriber. Sign in
Subscribe to Tufts Your Dog
Get the next year of Tufts Your Dog for just $20. And access all of our online content - over 1,000 articles - free of charge.
Subscribe today and save 44%. It's like getting 5 months FREE!
